Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Karuna pullback on PureTech sale a buying opportunity, says Wells Fargo » 13:45
01/23/20
01/23
13:45
01/23/20
13:45
KRTX

Karuna Therapeutics

$98.59 /

-17.38 (-14.99%)

Wells Fargo analyst Jacob…

Wells Fargo analyst Jacob Hughes noted that PureTech Health sold 2.1M shares of its holdings in Karuna Therapeutics but also noted that PureTech, a pre-IPO investor, still owns 5.295M shares, or a roughly 20% stake. While this could be a near term overhang, he would use the pullback in Karuna as an opportunity to build positions given his favorable view of the company's "significant opportunity" across several indications, including schizophrenia psychosis, pain and dementia related psychosis. Hughes has an Overweight rating on Karuna Therapeutics shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23
    Jan
Recommendations
Karuna's stock sale a buying opportunity, says William Blair » 10:24
01/23/20
01/23
10:24
01/23/20
10:24
KRTX

Karuna Therapeutics

$94.69 /

-21.28 (-18.35%)

William Blair analyst…

William Blair analyst Myles Minter maintained an Outperform rating with a $105 fair value estimate for Karuna Therapeutics (KRTX) following the company's $200M equity sale to Goldman Sachs. The analyst said that while the sale was discounted, and has taken the stock price down about 20% in pre-market trading, it does not alter his "fundamental view that Karuna holds the first truly novel antipsychotic in over 30 years in KarXT," and he would be a buyer on weakness.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23
    Jan
Hot Stocks
Karuna drops 18% to $94.50 after PureTech sells 2.1M shares  09:18
01/23/20
01/23
09:18
01/23/20
09:18
KRTX

Karuna Therapeutics

$115.97 /

+7.14 (+6.56%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23
    Jan
Hot Stocks
PureTech Health sells 2.1M shares of Karuna Therapeutics » 09:17
01/23/20
01/23
09:17
01/23/20
09:17
KRTX

Karuna Therapeutics

$115.97 /

+7.14 (+6.56%)

PureTech Health lowered…

PureTech Health lowered its stake in Karuna Therapeutics to 20.4%, which represents 5.3M of the company's outstanding shares. The reduced stake coincides with a 2.1M share block trade that was run by Goldman Sachs and priced at $99.75. PureTech on July 11 disclosed a 31.6% stake in Karuna, which represented 7.4M shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23
    Jan
Syndicate
Karuna Therapeutics 2.1M share Block Trade priced at $99.75 » 07:00
01/23/20
01/23
07:00
01/23/20
07:00
KRTX

Karuna Therapeutics

$115.97 /

+7.14 (+6.56%)

Goldman Sachs acted as…

Goldman Sachs acted as sole book running manager for the offering.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Wednesday
Recommendations
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo » 06:50
01/22/20
01/22
06:50
01/22/20
06:50
RVNC

Revance

$22.08 /

-0.38 (-1.69%)

, AMPH

Amphastar

$20.03 /

-0.03 (-0.15%)

, EBS

Emergent BioSolutions

$57.30 /

+1.7 (+3.06%)

, BHC

Bausch Health

$29.75 /

-0.51 (-1.69%)

, AGN

Allergan

$192.54 /

-0.15 (-0.08%)

, EOLS

Evolus

$11.15 /

-0.15 (-1.33%)

, JAZZ

Jazz Pharmaceuticals

$150.40 /

-0.6 (-0.40%)

, KRTX

Karuna Therapeutics

$108.83 /

+4.3 (+4.11%)

, PRGO

Perrigo

$59.84 /

+0.825 (+1.40%)

, TEVA

Teva

$10.03 /

-0.175 (-1.72%)

, MNK

Mallinckrodt

$6.03 /

+0.825 (+15.85%)

, OSMT

Osmotica Pharmaceuticals

$6.52 /

+0.66 (+11.26%)

Wells Fargo analyst Jacob…

Wells Fargo analyst Jacob Hughes named Revance Therapeutics (RVNC) and Amphastar Pharmaceuticals (AMPH) his top ideas for 2020 in the Specialty Pharmaceuticals space. For Revance, the analyst believes the recent filler acquisition is "highly synergistic" while a "slew of pipeline catalysts are upcoming." For Amphastar, he says the Primatene launch is progressing well and that "several" pipeline catalysts will drive value. For a near-term trade, Hughes likes Emergent BioSolutions (EBS) for a potentially favorable ruling in the Narcan patent litigation per his patent consultant feedback. The analyst this morning also upgraded Bausch Health Companies (BHC) to Equal Weight from Underweight and downgraded Allergan (AGN) to Equal Weight from Overweight. He also lowered his price target for Equal Weight-rated Evolus (EOLS) to $12 from $15, raised his price target for Overweight-rated Jazz Pharmaceuticals (JAZZ) to $189 from $186, raised his price target for Overweight-rated Karuna Therapeutics (KRTX) to $137 from $106, raised his price target for Equal Weight-rated Perrigo (PRGO) to $63 from $51, raised his price target for Overweight-rated Revance to $35 from $20, raised his price target for Equal Weight-rated Teva (TEVA) to $10 from $8, raised his price target for Equal Weight-rated Mallinckrodt (MNK) to $6 from $3, and raised his price target for Overweight-rated Osmotica Pharmaceuticals (OSMT) to $8 from $7.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Conference/Events
JPMorgan to hold a conference » 10:25
01/16/20
01/16
10:25
01/16/20
10:25
ELGX

Endologix

$1.86 /

+0.01 (+0.54%)

, FPRX

Five Prime

$5.00 /

+0.04 (+0.81%)

, HMSY

HMS Holdings

$29.87 /

+0.64 (+2.19%)

, IDRA

Idera Pharmaceuticals

$1.91 /

+0.035 (+1.87%)

, LXRX

Lexicon

$4.37 /

+0.115 (+2.70%)

, RIGL

Rigel Pharmaceuticals

$3.00 /

+0.27 (+9.89%)

, TRXC

TransEnterix

$1.59 /

-0.03 (-1.85%)

, NVDA

Nvidia

$248.87 /

+3.35 (+1.36%)

, JNCE

Jounce Therapeutics

$7.96 /

+0.275 (+3.58%)

, GRTS

Gritstone Oncology

$11.94 /

+0.6 (+5.29%)

, STRO

Sutro Biopharma

$11.83 /

+ (+0.00%)

, ZIOP

Ziopharm

$5.04 /

+0.09 (+1.82%)

, IMGN

ImmunoGen

$4.93 /

-0.02 (-0.40%)

, ATRC

AtriCure

$36.13 /

+0.79 (+2.24%)

, ACOR

Acorda Therapeutics

$2.14 /

+0.015 (+0.71%)

, ARNA

Arena Pharmaceuticals

$46.25 /

+1.1 (+2.44%)

, KURA

Kura Oncology

$13.02 /

+0.15 (+1.17%)

, NXTC

NextCure

$54.34 /

+0.95 (+1.78%)

, VEEV

Veeva

$146.52 /

+2 (+1.38%)

, RVNC

Revance

$22.84 /

-0.06 (-0.26%)

, ISEE

Iveric bio

$6.81 /

+ (+0.00%)

, INSP

Inspire Medical

$82.38 /

+1.13 (+1.39%)

, CLSD

Clearside Biomedical

$2.45 /

+0.07 (+2.94%)

, MSON

Misonix

$18.93 /

+ (+0.00%)

, KRTX

Karuna Therapeutics

$85.65 /

+0.37 (+0.43%)

38th Annual Healthcare…

38th Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 16 at 10:30 am; not all company presentations may be webcasted. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
JPMorgan to hold a conference » 09:15
01/16/20
01/16
09:15
01/16/20
09:15
ELGX

Endologix

$1.85 /

-0.02 (-1.07%)

, FPRX

Five Prime

$4.96 /

-0.12 (-2.36%)

, HMSY

HMS Holdings

$29.23 /

-0.39 (-1.32%)

, IDRA

Idera Pharmaceuticals

$1.87 /

-0.02 (-1.06%)

, LXRX

Lexicon

$4.26 /

+0.085 (+2.04%)

, RIGL

Rigel Pharmaceuticals

$2.73 /

+0.115 (+4.40%)

, TRXC

TransEnterix

$1.62 /

+0.03 (+1.89%)

, NVDA

Nvidia

$245.52 /

-1.84 (-0.74%)

, JNCE

Jounce Therapeutics

$7.69 /

+0.245 (+3.29%)

, GRTS

Gritstone Oncology

$11.34 /

+0.9 (+8.62%)

, STRO

Sutro Biopharma

$11.83 /

+0.04 (+0.34%)

, ZIOP

Ziopharm

$4.95 /

+0.19 (+3.99%)

, IMGN

ImmunoGen

$4.95 /

+0.355 (+7.73%)

, ATRC

AtriCure

$35.34 /

+1.47 (+4.34%)

, ACOR

Acorda Therapeutics

$2.12 /

-0.215 (-9.21%)

, ARNA

Arena Pharmaceuticals

$45.15 /

-0.45 (-0.99%)

, KURA

Kura Oncology

$12.87 /

-0.26 (-1.98%)

, NXTC

NextCure

$53.39 /

+0.27 (+0.51%)

, VEEV

Veeva

$144.52 /

-3.33 (-2.25%)

, RVNC

Revance

$22.90 /

+1.16 (+5.34%)

, ISEE

Iveric bio

$6.81 /

-0.04 (-0.58%)

, INSP

Inspire Medical

$81.25 /

+1.19 (+1.49%)

, CLSD

Clearside Biomedical

$2.38 /

-0.03 (-1.24%)

, MSON

Misonix

$18.93 /

+0.14 (+0.75%)

, KRTX

Karuna Therapeutics

$85.28 /

+0.18 (+0.21%)

38th Annual Healthcare…

38th Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 16 at 10:30 am; not all company presentations may be webcasted. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Five new option listings and one option delisting on January 15th » 08:30
01/15/20
01/15
08:30
01/15/20
08:30
BBIO

BridgeBio

$34.53 /

+0.96 (+2.86%)

, DAC

Danaos

$9.13 /

+0.18 (+2.01%)

, DEAC

Diamond Eagle Acquisition

$11.90 /

-0.1 (-0.83%)

, KRTX

Karuna Therapeutics

$85.10 /

+10.83 (+14.58%)

, SAVA

Cassava Sciences

$7.40 /

+0.42 (+6.02%)

, SRCI

SRC Energy

$3.98 /

-0.1 (-2.45%)

New option listings for…

New option listings for January 15th include BridgeBio Pharma Inc (BBIO), Danaos (DAC), Diamond Eagle Acquisition Corp (Class A Stock) (DEAC), Karuna Therapeutics Inc (KRTX), and Cassava Sciences Inc (SAVA). Option delistings effective January 15th include SRC Energy Inc (SRCI).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Karuna Therapeutics' KarXT surpasses expectations, says William Blair » 14:53
01/14/20
01/14
14:53
01/14/20
14:53
KRTX

Karuna Therapeutics

$88.00 /

+13.73 (+18.49%)

William Blair analyst…

William Blair analyst Myles Minter maintained an Outperform rating and $105 price target on Karuna Therapeutics after the company disclosed the effect size from its positive Phase II trial of KarXT for the treatment of schizophrenia, which surpassed the analyst's expectations and "exemplifies the therapy's best-in-class risk/benefit profile." Minter called it "the first truly novel antipsychotic in over 30 years that possesses efficacy in the range of the atypical antipsychotics without the compliance-restricting adverse effects triggered by dopamine receptor antagonism." In afternoon trading, shares of Karuna are higher by 17.1% to $86.84.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.
友情链接:幸运飞艇官方开奖2020幸运飞艇计划网幸运飞艇走势图幸运飞艇历史开奖结果筛选